Literature DB >> 28379036

Inverse association of lipoprotein (a) with markers of insulin resistance in dyslipidemic subjects.

H Vaverková1, D Karásek, M Halenka, L Cibíčková, V Kubíčková.   

Abstract

Lipoprotein (a) [Lp(a)] is an LDL-like particle that contains an apolipoprotein B100 molecule covalently bound to a plasminogen-like glycoprotein, apolipoprotein (a) [apo(a)]. Epidemiological evidence supports a direct and causal association between Lp(a) levels and coronary risk. On the contrary, a few prospective findings demonstrate inverse association of Lp(a) levels with risk of type 2 diabetes (T2DM). The aim of our study was to evaluate the association of Lp(a) with indicators of insulin resistance (IR) and metabolic syndrome (MS), which precede development of T2DM. We enrolled 607 asymptomatic dyslipidemic subjects (295 men and 312 women, mean age 45.6+/-14.0 years) into our cross-sectional study. Lp(a) concentrations correlated inversely with TG, AIP, insulin, HOMA, C-peptide, BMI, waist circumference, and number of MS components (p<0.01 for all). Subjects with MS had significantly lower Lp(a) concentrations in comparison with those without the presence of this phenotype (p<0.0001). Serum concentrations of Lp(a) in the lower (1(th)-3(rd)) quartiles of insulin and HOMA were significantly higher than in the 4(th) quartile of these insulin resistance markers (p<0.001). Odds ratios of having increased markers of IR (TG, HOMA) and MS in top quartile of Lp(a) also indicate inverse association of Lp(a) with IR. The results of our study support an inverse association of Lp(a) levels with IR and MS that precedes overt T2DM diagnosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28379036     DOI: 10.33549/physiolres.933583

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  11 in total

1.  In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes.

Authors:  Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2018-04-02       Impact factor: 5.922

2.  Association between new markers of cardiovascular risk and hepatic insulin resistance in those at high risk of developing type 2 diabetes.

Authors:  Lucilla D Monti; Camillo Bechi Genzano; Barbara Fontana; Elena Galluccio; Serena Spadoni; Andrea Magistro; Emanuele Bosi; Piermarco Piatti
Journal:  Endocrine       Date:  2021-09-21       Impact factor: 3.633

3.  Lipoprotein(a) Change After Sleeve Gastrectomy Is Affected by the Presence of Metabolic Syndrome.

Authors:  Silvia Paredes; Marta Alves; Maria Lopes Pereira; Olinda Marques; Laura Ribeiro
Journal:  Obes Surg       Date:  2020-02       Impact factor: 4.129

4.  Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors.

Authors:  Kwok Leung Ong; Robyn L McClelland; Matthew A Allison; Mary Cushman; Parveen K Garg; Michael Y Tsai; Kerry-Anne Rye; Fatiha Tabet
Journal:  Metabolism       Date:  2021-01-07       Impact factor: 8.694

5.  Implication between Genetic Variants from APOA5 and ZPR1 and NAFLD Severity in Patients with Hypertriglyceridemia.

Authors:  Virginia Esteve-Luque; Ariadna Padró-Miquel; Marta Fanlo-Maresma; Emili Corbella; Xavier Corbella; Xavier Pintó; Beatriz Candás-Estébanez
Journal:  Nutrients       Date:  2021-02-08       Impact factor: 5.717

6.  Lipoprotein(a) and Metabolic Syndrome.

Authors:  Nikolaus Buchmann; Till Ittermann; Ilja Demuth; Marcello R P Markus; Henry Völzke; Marcus Dörr; Nele Friedrich; Markus M Lerch; Raul D Santos; Sabine Schipf; Elisabeth Steinhagen-Thiessen
Journal:  Dtsch Arztebl Int       Date:  2022-04-15       Impact factor: 8.251

7.  Sleep Duration, Lipid Profile and Insulin Resistance: Potential Role of Lipoprotein(a).

Authors:  Lyudmila Korostovtseva; Asiiat Alieva; Oxana Rotar; Mikhail Bochkarev; Maria Boyarinova; Yurii Sviryaev; Aleksandra Konradi; Eugene Shlyakhto
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

Review 8.  COSMIC project: consensus on the objectives of the metabolic syndrome in clinic.

Authors:  Juan Pedro-Botet; Juan F Ascaso; Vivencio Barrios; Alejandro De la Sierra; Javier Escalada; Jesús Millán; Jose M Mostaza; Pablo Pérez-Martínez; Xavier Pintó; Jordi Salas-Salvadó; Pedro Valdivielso
Journal:  Diabetes Metab Syndr Obes       Date:  2018-10-31       Impact factor: 3.168

9.  Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment.

Authors:  Gregory G Schwartz; Michael Szarek; Vera A Bittner; Deepak L Bhatt; Rafael Diaz; Shaun G Goodman; J Wouter Jukema; Megan Loy; Garen Manvelian; Robert Pordy; Harvey D White; Philippe Gabriel Steg
Journal:  Diabetes Care       Date:  2021-03-15       Impact factor: 19.112

10.  Biomarker potential of C-peptide for screening of insulin resistance in diabetic and non-diabetic individuals.

Authors:  Haseeb A Khan; Samia H Sobki; Aishah Ekhzaimy; Isra Khan; Mona A Almusawi
Journal:  Saudi J Biol Sci       Date:  2018-06-01       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.